Madrigal Pharmaceuticals, Inc. MDGL 深 沪
交易中 07-06 10:02:21 美东时间
526.13
-1.970
-0.37%
华盛通- 最 高530.9999
- 今 开523.68
- 成交量 1.34万股
- 最 低 522.06
- 昨 收 528.10
- 总市值 121.30亿
- 52周最高 615.00
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 286.44
- 委 比 0.00%
- 总股本 2305.57万
- 历史最高 615.00
- 量 比 0.40
- 振 幅 1.69%
- 历史最低 5.25
- 每 手 1
- 风险率 75.91%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Suzhou Ribo hits first milestone in Madrigal siRNA collaboration for MASH drug candidate
Suzhou Ribo hits first milestone in Madrigal siRNA collaboration for MASH drug candidate Suzhou Ribo Life Science reached a first candidate drug nomination milestone in its siRNA partnership with Madrigal Pharmaceuticals. The program targets liver diseases, with an initial focus on metabolic dysfunc
07-02 08:01
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted equity awards to five new non-executive employees on June 15, 2026, under its 2025 Inducement Plan. The awards, totaling 1,397 time-based restricted stock units, vest in four equal installments over four years, contingent on continued employment. Madrigal focuses on developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), with its approved medication Rezdiffra targeting the disease's un...
06-22 20:05
美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
B of A Securities Maintains Neutral on Madrigal Pharmaceuticals, Lowers Price Target to $542
B of A Securities analyst Alexandria Hammond maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral and lowers the price target from $550 to $542.
06-11 20:10
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted equity awards to 20 new non-executive employees under its 2025 Inducement Plan on June 1, 2026. The awards, totaling 6,881 time-based restricted stock units, vest in four equal installments over four years, contingent on continued employment. Madrigal, a biopharmaceutical company focused on treating metabolic dysfunction-associated steatohepatitis (MASH), also highlighted its approved medication Rezdiffra and ongo...
06-04 20:05
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
Madrigal Pharmaceuticals will present at the 47th Annual Global Goldman Sachs Health Care Conference on June 10, 2026, at 11:20 A.M. EDT. The presentation will be webcast live and available for replay. Madrigal, a biopharmaceutical company, focuses on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH). Its drug, Rezdiffra, is the first FDA and European Commission-approved treatment for MASH with moderate to advanced ...
06-03 12:00
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted equity awards to 15 new non-executive employees on May 15, 2026, under its 2025 Inducement Plan. The awards, totaling 5,308 time-based restricted stock units, vest over four years and are contingent on continued employment. Madrigal, focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH), markets Rezdiffra, the first FDA and European Commission-approved treatment for MASH with ...
05-21 20:05
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Truist Securities Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $709
Truist Securities analyst Srikripa Devarakonda maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $640 to $709.
05-13 23:05
